These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
151 related items for PubMed ID: 2650413
1. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts. Henslee PJ, Byers VS, Jennings CD, Marciniak E, Thompson JS, Macdonald JS, Romond EH, Messino MJ, Scannon PJ. Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413 [No Abstract] [Full Text] [Related]
2. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937 [Abstract] [Full Text] [Related]
3. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Champlin R, Jansen J, Ho W, Gajewski J, Nimer S, Lee K, Territo M, Winston D, Tricot G, Reichert T. Transplant Proc; 1991 Feb; 23(1 Pt 2):1695-6. PubMed ID: 1899162 [No Abstract] [Full Text] [Related]
4. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C. Prog Clin Biol Res; 1990 Feb; 333():207-15. PubMed ID: 1689852 [No Abstract] [Full Text] [Related]
5. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB. Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262 [Abstract] [Full Text] [Related]
6. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B. Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565 [Abstract] [Full Text] [Related]
7. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease. Fauser AA, Shustik C, Langleben A, Laurent G, Kanz L, Spurll GM, Price G, Ahlgren PD, Cooper BA. Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672 [Abstract] [Full Text] [Related]
8. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Champlin R, Giralt S, Przepiorka D, Ho W, Lee K, Gajewski J, Nimer S, Andersson B, Wallerstein R, Ippolito C. Prog Clin Biol Res; 1992 Feb; 377():385-94; discussion 395-8. PubMed ID: 1438435 [No Abstract] [Full Text] [Related]
9. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AW, Gordon-Smith EC. Bone Marrow Transplant; 1986 May; 1(1):53-66. PubMed ID: 3332120 [Abstract] [Full Text] [Related]
10. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Gallardo D, García-López J, Sureda A, Canals C, Ferra C, Cancelas JA, Berlanga JJ, Brunet S, Boqué C, Picón M, Torrico C, Amill B, Martino R, Martínez C, Martín-Henao G, Domingo-Albós A, Grañena A. Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473 [Abstract] [Full Text] [Related]
11. Italian survey on allogeneic BMT for chronic myeloid leukaemia. Arcese W, Mandelli F, Papa G, Bacigalupo A, Van Lint MT, Lucarelli G, Galimberti P, Polchi P, Tura S, Bandini G. Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():90-1. PubMed ID: 2697445 [No Abstract] [Full Text] [Related]
12. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation]. Iriondo A, Richard C, Hermosa V, Conde E, Garijo J, Cuadrado MA, Bello C, Muruzábal MJ, Pérez-Encinas M, Zubizarreta A. Med Clin (Barc); 1988 Oct 22; 91(13):488-92. PubMed ID: 3067007 [No Abstract] [Full Text] [Related]
13. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies]. Hervé P, Flesch M. Nouv Rev Fr Hematol (1978); 1986 Oct 22; 28(2):97-105. PubMed ID: 2942838 [Abstract] [Full Text] [Related]
14. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis. Marciniak E, Romond EH, Thompson JS, Henslee PJ. Bone Marrow Transplant; 1988 Nov 22; 3(6):589-98. PubMed ID: 3063328 [Abstract] [Full Text] [Related]
15. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders. Slavin S, Or R, Naparstek E, Weiss L, Mumcuoglu M, Weshler Z, Brautbar H, Cividalli G, Glikson M, Hale G. Transplant Proc; 1987 Feb 22; 19(1 Pt 3):2614-5. PubMed ID: 3274569 [No Abstract] [Full Text] [Related]
16. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin. Siena S, Villa S, Bonadonna G, Bregni M, Gianni AM. Transplant Proc; 1987 Feb 22; 19(1 Pt 3):2735-7. PubMed ID: 3274583 [No Abstract] [Full Text] [Related]
17. Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults. Maraninchi D, Mawas C, Stoppa AM, Gaspard MH, Marit G, Van Ekthoven A, Reiffers J, Olive D, Hirn M, Delaage M. Bone Marrow Transplant; 1989 Mar 22; 4(2):147-50. PubMed ID: 2650783 [Abstract] [Full Text] [Related]
18. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Henslee-Downey PJ, Parrish RS, MacDonald JS, Romond EH, Marciniak E, Coffey C, Ciocci G, Thompson JS. Transplantation; 1996 Mar 15; 61(5):738-45. PubMed ID: 8607177 [Abstract] [Full Text] [Related]
19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S. Clin Transpl; 1996 Mar 15; ():281-90. PubMed ID: 9286578 [Abstract] [Full Text] [Related]
20. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Gajewski J, Gjertson D, Cecka M, Tonai R, Przepiorka D, Hunt L, Giralt S, Chan KW, Feig S, Territo M, Andersson B, van Besien K, Khouri I, Fischer H, Babbitt L, Ippolitti C, Schiller G, Lill M, Warkentin D, Neumann J, Petz L, Terasaki P, Champlin R. Biol Blood Marrow Transplant; 1997 Jun 15; 3(2):76-82. PubMed ID: 9267667 [Abstract] [Full Text] [Related] Page: [Next] [New Search]